Search results
FDA lays out donanemab concerns ahead of meeting, as Lilly vigorously defends safety
FierceBiotech· 20 hours agoThe docs for Eli Lilly’s donanemab advisory committee meeting are in: the FDA has raised concerns...
Healing the brain: Biotech to test new therapy for stroke
San Jose Mercury News· 16 hours agoA 3-year-old Sewickley, Pennsylvania, biotech firm is partnering with a Boston hospital to test a...
Ozempic vs. metformin: What’s the difference?
Medical News Today· 4 days agoOzempic (semaglutide) is a brand-name drug, while metformin is a generic drug. This article explains the main similarities and differences between...
New program introduced for stroke patients in central Virginia
WVIR NBC 29· 7 days agoA new program at UVA Health is helping ischemic stroke survivors improve the use of their arms. It’s...
Edwards Life Sciences sees positive results from TAVR trial
Medical Device Network via Yahoo Finance· 24 hours agoElsewhere in the growing field of TAVR treatment, the US Food and Drug Administration (FDA) has ...
William Blair Commentary: Waistlines and GLP1-s--Expanding in Unison
GuruFocus.com via Yahoo Finance· 3 days agoNovo Nordisk already has a drug with the same active ingredient (which is called semaglutide) in...
Duavee: Mild to serious side effects and how to manage them
Medical News Today· 1 day agoAs with other drugs, Duavee can cause side effects, such as abdominal pain, dizziness, and nausea. A...
MDMA's Cardiac Safety Concerns; Entresto Generics; Heart Disease 'Older Than Moses'
MedPage Today· 3 days agoAnnual healthcare costs associated with cardiovascular risk factors are projected to reach $400 billion in the year 2050, when costs for cardiovascular conditions are estimated at $1,490 billion ...
Saxenda vs. Wegovy: What to know about each
Medical News Today· 4 days agoSaxenda (liraglutide) and Wegovy (semaglutide) are brand-name injections. Saxenda is used daily, while Wegovy is used weekly. This article explains the...
MDMA drug for PTSD panned by FDA advisers citing trial flaws - The Boston Globe
The Boston Globe· 2 days agoAdvisers to the Food and Drug Administration voted 9 to 2 that developer Lykos Therapeutics Inc.’s...